Next‐generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review
Clark S, Hartwell E, Choi D, Krystal J, Messing R, Ferguson L. Next‐generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review. Alcohol Clinical And Experimental Research 2024 PMID: 39532676, DOI: 10.1111/acer.15476.Peer-Reviewed Original ResearchAlcohol use disorderRisk biomarkersAlcohol consumptionDiagnostic biomarkersAlcohol use disorder diagnosisAlcohol research fieldPredictive biomarkersAlcohol-related problemsMetabolomic informationUse disorderOmics-based biomarkersRegular drinkingClinical implicationsProblematic drinkingDisorder diagnosisBiomarkersNext-generation biomarkersRiskAcamprosateAlcoholPrognosisDiagnosisDrinkingDexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisorders